Latest News and Press Releases

SLOUGH, U.K., July 14, 2004 (PRIMEZONE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, BELGIUM, CANADA OR JAPAN Celltech Group plc ("Celltech") Cancellation of...

SLOUGH, U.K., June 23, 2004 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) announces that the U.S. Food and Drug Administration ("FDA") has approved Codeprex(tm) (codeine polistirex/...

SLOUGH, U.K., May 19, 2004 (PRIMEZONE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN, INTO OR FROM BELGIUM, CANADA, AUSTRALIA OR JAPAN UCB S.A. ...

Slough, U.K., May 18, 2004 (PRIMEZONE) -- Celltech Group plc -- Celltech's shareholders to receive 550 pence per ordinary share (equivalent to USD 19.44 per American ...

SLOUGH, U.K., May 18, 2004 (PRIMEZONE) -- Celltech Group plc (LSE:CCH)(NYSE:CLL) announces that it has entered into an agreement with UCB S.A. for the worldwide development and marketing of CDP870,...

SLOUGH, U.K., April 1, 2004 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) today announces that the European Medicines Evaluation Agency (EMEA) has accepted for review its marketing...

SLOUGH, U.K., March 31, 2004 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) today announces positive preliminary results from the first Phase III clinical trial with CDP870 in rheumatoid...

SLOUGH, U.K., March 16, 2004 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) today announces preliminary results for the year ended 31 December 2003. Results highlights are as follows: --...

SLOUGH, U.K., Feb. 5, 2004 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) and Biogen Idec (Nasdaq:BIIB) announce that they have entered into a collaboration for the research, development and...

SLOUGH, U.K., Jan. 8, 2004 (PRIMEZONE) -- Celltech Group plc (LSE:CCH) (NYSE:CLL) today announces the achievement of a further milestone in its agreement with Amgen Inc. for the research, development...